VISEN Pharmaceuticals announced that it has received $150 million in an equity round of funding led by new investor Sequoia Capital China on January 8, 2021. The transaction included participation from new investors Cormorant Asset Management, LLC, OrbiMed Advisors LLC, Sherpa Healthcare Partners Co., Ltd., Investment Arm, HBM Healthcare Investments AG (SWX:HBMN), a fund managed by HBM Partners Ltd., Pivotal bioVenture Partners China, Logos Global Management, L.P., CDG Capital Private Equity, returning investors including Ascendis Pharma A/S (NasdaqGS:ASND), Vivo Capital, LLC, and Sofinnova Investment, Inc. Ascendis Pharma A/S (NasdaqGS:ASND) participated for $12.5 million in the transaction. As the part of the transaction, Michael Wolff Jensen and Jan Mikkelsen from Ascendis Pharma A/S (NasdaqGS:ASND) joined company's board of director.